THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS MONITORING OF HIV DRUG RESISTANCE IN CHILDREN RECEIVING FIRST LINE ANTIRETROVIRAL THERAPY AT TWO CHILDREN.

Slides:



Advertisements
Similar presentations
Management of ART in Albania : From the European Guidelines to the real practice. Arjan Harxhi MD, MSc, PhD University Hospital Center of Tirana Mother.
Advertisements

World Health Organization Surveys of Transmitted and Acquired HIV Drug Resistance in Resource Limited Settings CROI 2011 S Bertagnolio*, K Kelley*, A Saadani.
Indicators for monitoring ARV treatment outcomes.
Children and resistance to HIV: CHIPS data Dr Katherine Boyd on behalf of Collaborative HIV Paediatric Study (CHIPS) and the UK HIV Drug Resistance Database.
Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.
Improving Retention, Adherence, and Psychosocial Support within PMTCT Services: Implementation Workshop for Health Workers All slide illustrations by Petra.
ANTIRETROVIRAL THERAPY Dr. Samuel Mwaniki (BPharm., MSc TID, UoN) University of Nairobi ISO 9001: Certified
“Getting to Zero: Thailand’s Experience with E-MTCT” Petchsri Sirinirund Advisor on HIV/AIDS Policy and Programme Department of Disease Control, Thailand.
HIV Drug Resistance Impact on ART for the Pregnant Woman Elliot Raizes, MD CDC Division of Global HIV/AIDS June 18, 2012.
HIV Resistance Testing Clinical Implications Cyril K. Goshima, M.D. Director, AIDS Education Project June, 2009.
HIV in Suriname Ministry of Health Suriname M.Sigrid Mac Donald – Ottevanger, MD Focal point HIV Treatment and Care, NAP.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
Global HIV Resistance: The Implications of Transmission
Failure Therapy VIRAL RESITANCE ADHERENCE!!!!!!!!!!! DRUG INTERACTION.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
Transition Program of HIV-infected adolescents to Adult HIV care in Buenos Aires, Argentina S. Arazi Caillaud 1, D. Mecikovsky 1, A.Bordato.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Virological predictors of clinical outcome Anna Maria Geretti Royal Free Hampstead NHS Trust & UCL Medical School London.
Determinants of long term adherence to antiretroviral drugs among adults followed over 54 months in Dakar (Senegal) M. Ciss 1, A. Desclaux 2, K. Diop 3,
Office of Overseas Programming & Training Support (OPATS) Treatment Adherence HIV Care, Support, and Treatment.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Predicting NNRTI Resistance – do polymorphisms matter? Nicola E Mackie 1, Lucy Garvey 1, Anna Maria Geretti 2, Linda Harrison 3, Peter Tilston 4, Andrew.
Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,
1 ARV Drug Resistance HAIVN Harvard Medical School AIDS Initiative in Vietnam.
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.
Update on HIV Therapy Elly T Katabira, FRCP Department of Medicine Makerere University Medical School Scaling up Treatment Programs: Issues, Challenges.
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
8èmes Rencontres Nord-Sud Avelin Aghokeng IRD-UMI233 & University of Montpellier I Yaoundé-Cameroon Avelin Aghokeng IRD-UMI233 & University of Montpellier.
Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.
ANTEPARTUM CARE. Pregnant Women Who Are ARV Naive (1)  Pregnant women with HIV infection should receive standard clinical, immunologic, and virologic.
Prevention and Care Dr S Charalambous WHO guidelines.
High Discordance in Plasma and Genital Tract HIV-1 Drug Resistance in Indian Women Failing First-line Therapy MOPDA0106 S. Saravanan, PhD Session Code:
Source: EPP/Spectrum HIV estimates, EPHI, 2014 HAART is the recommended form of treatment HAART is usually combination of at least 3 drugs 2 NRTIs +
Evaluation of the WHO immunologic criteria for treatment failure among adults on first-line HAART in south India Snigdha Vallabhaneni 1, Sara Chandy 2,
Transmitted drug resistance Pat Cane. Questions What is the level of TDR and is it changing? Are we measuring TDR accurately? Are more sensitive methods.
Washington D.C., USA, July 2012www.aids2012.org Changing Patterns of NRTI and PI Resistance Mutations Between 2006 and 2011 in ART experienced SA.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Late maternal HIV testing, HCMC Chi K. Nguyen 1, Haily T. Pham 2, ThuVan T. Tieu 2, Chinh.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Treatment-Experienced Patients in Resource- Limited Settings Susan M. Graham Assistant Professor, Medicine.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Yield and impact of repeated screening for tuberculosis and isoniazid preventive therapy among patients.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS The acquired HIV drug resistance among HIV adults receiving ART at least 36 months in Vietnam Vũ Quốc.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS VIRAL LOAD SUPPRESSION ON ART IN VIETNAM Speaker: Le Truong Giang PhD, MD President of HCMC Association.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
HAIVN Harvard Medical School AIDS Initiative in Vietnam
Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.
Long-Term Changes in Lipids and Glucose/Insulin among HIV-Infected Antiretroviral Naïve Persons Randomized to PI vs. NNRTI vs. PI+NNRTI-based strategies:
A Call to Action Children – The missing face of AIDS.
1 Uses of Data from the WHO HIV Drug Resistance Strategy: 1. Monitoring of HIVDR emerging in treated groups in sentinel ART clinics HIV Drug Resistance.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
2 3 Population : 6,934,169 inhabitants 6 Sanitary regions UNAIDS (2014) - HIV prevalence : 2.5% = 110,000 PLHIV - Higher prevalence in southern regions.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
Switch to PI/r monotherapy
Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial
Phylogenetic relationships of HIV-1 Pol RT strains
Providing ARVs to children in resource limited settings
Background Results Methods Conclusion
Introduction Results Objectives Methods Conclusion Funding
Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda
Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses 
St Stephen’s Centre, Chelsea & Westminster Hospital, United Kingdom
Comparison of NNRTI vs PI/r
ARV-trial.com Switch to FTC + ddI + EFV ALIZE 1.
ANTIRETROVIRAL RESISTANCE IN CLINICAL PRACTICE
HVDRS STUDY RESISTANCE: WE CARE
Share your thoughts on this presentation with #IAS2019
Presentation transcript:

THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS MONITORING OF HIV DRUG RESISTANCE IN CHILDREN RECEIVING FIRST LINE ANTIRETROVIRAL THERAPY AT TWO CHILDREN HOSPITALS NHI ĐỒNG 1 AND NHI ĐỒNG 2 IN HO CHI MINH CITY,VIETNAM Ton Tran (1), Anh Q. Luong (1), Khanh Thu H. Huynh (1), Ngoc Thao T. Do (1), Nghia V. Khuu (1), Thinh X. Vu (1), Khanh H. Truong (2), Quy T. Du (2), Kim Thoa P. Le (2), Viet C. Do (3), An T. Vu (3), Thanh Thuy T. Le (3), Xuan Lien T. Truong (1). (1) Pasteur Institute, Ho Chi Minh City, (2) Nhi Dong 1 hospital, Ho Chi Minh City, (3) Nhi Dong 2 hospital, Ho Chi Minh City

The 6 th National Scientific Conference on HIV/AIDS Outline 1.Background 2.Objectives 3.Methods 4.Results & Discussions 5.Conclusions 6.Recommendations

The 6 th National Scientific Conference on HIV/AIDS INTRODUCTION The biggest barrier in treatment for HIV/AIDS patients is ARV drug resistance problem 1.Background

The 6 th National Scientific Conference on HIV/AIDS INTRODUCTION

The 6 th National Scientific Conference on HIV/AIDS Early detection of HIVDR and changing appropriate ARV regimens helps prevent: Accumulation of resistance mutations Poor response or non-response to HAART Serious clinical events and mortality Prolonged viremia and risk of transmission INTRODUCTION

The 6 th National Scientific Conference on HIV/AIDS In Vietnam: On adult patients (1) Early Warning Indicator of HIVDR (EWI): từ 2010 (2) Mornitoring of HIVDR: (3) HIVDR threshold survey: from (4) Cross-sectional studies on HIVDR on ARV- naive patients, ART patients,... Lack of HIVDR data on pediatrics INTRODUCTION

The 6 th National Scientific Conference on HIV/AIDS 2. Objectives 1.Identify specific HIVDR mutations and mutation patterns in populations at initiation of first-line ART 2.Estimate the proportion of the ART site population achieving HIVDR prevention, as measured by viral load suppression, in populations after one year of first-line ART 3.Identify specific HIVDR mutations and mutation patterns in populations not achieving prevention of HIVDR on first-line ART. 4.Identify programmatic factors potentially associated with the prevention (or non-prevention) of HIVDR.

The 6 th National Scientific Conference on HIV/AIDS METHOD 1- Study design: cohort study 2- Study subjects: HIV/AIDS children at initiation of first line anti-retroviral therapy at two children hospitals Nhi Đồng 1 and Nhi Đồng 2 in Ho Chi Minh city 3- Duration: 12/2011 – 03/ Methods

The 6 th National Scientific Conference on HIV/AIDS Enrollment criteria Patients attending the selected OPCs who meet the following criteria: ≤ 15 years old Children whose parents or eligible guardians consent following the written informed consent process and who provide assent (for children 7 years old or older), and Who are eligible to initiate, and do initiate, pediatric first-line ART regimen at a participating site. METHOD

The 6 th National Scientific Conference on HIV/AIDS Exclusion criteria: Individuals enrolled in a clinical trial or clinical research study (either at the monitoring site or another location). Individuals who are part of an observational cohort for whom more follow-up efforts are made than for other ART patients treated at the site (Patients enrolled in an observational cohort for whom no additional follow-up procedures are included may be eligible). Individuals restarting ART, who have previously started and stopped ART at the sentinel survey site. Individuals transferring in from another paediatric ART site who are at the time of transfer currently taking a three- or four-drug first-line ART regimen. METHOD

The 6 th National Scientific Conference on HIV/AIDS PROCEDURE Enrollment criteriaConsultant Agree Disagree Cont. as normal Data + sample HIV VL testing HIVDR genotyping Cont. as normal ≥1000 cps/ml <1000 cps/ml Monitoring as normal & HIVDR analysis Data entry and analysis for baseline Monitoring as normal Data + sample for HIV VL Stop 1 st line regimens or after 12 months

The 6 th National Scientific Conference on HIV/AIDS Testing at HIV/AIDS laboratory of Pasteur Institute: -HIV-1 Viral load by Real time PCR (Generic HIV Charge Virale of Biocentric – France, LOD: 250 cps/mL) -HIVDR genotyping: Sequencing of Pol gen (1800 bp) => coding for proteins which are targets of NRTIs, NNRTIs & PIs being used in Vietnam. Sequence analysis by DNAStar Lasergene 12 Core Suite Sequence interpretation with HIVdb program of Stanford HIV drug resistance database (USA).

The 6 th National Scientific Conference on HIV/AIDS RESULTS Baseline Characteristics 136 eligible children consecutively initiating first line ART were enrolled; male/female: 69/67 31,62 % were HIV diagnosed before 18 months of age. 72,06% were detected after 18-month old. 75,21 % of children >18 months of age, 39,67 % of children >5 years old at ART initation 4. Results & Discussions

The 6 th National Scientific Conference on HIV/AIDS 6/136 of patients‘mothers joined in PMTCT program, including 3 ones were HIV detected at labor Number of children having ARV in PMTCT program was 11/136 (8,09%) 47/136 (34,55%) had advanced disease – WHO clinical stages III and IV at ART initation 65/136 (47,79%) were severely immunocompromised (L T CD4 <15%) at ART initation RESULTS

The 6 th National Scientific Conference on HIV/AIDS 100% had HIV VL > 3log cps/ml, of whom 81,62% had HIV VL > 5log cps/ml at ART initation 32 (37,21%) had OIs, of whom 58,54% had tuberculosis at ART initation. 5,15 % (7/136) had HBsAg (+), 3,68% (5/136) had anti HCV (+) & 2,20% (3/136) had Cryptococcus Antigen (+). 134/136 (98,53%) had HIV-1 subtype CRF01-AE

The 6 th National Scientific Conference on HIV/AIDS 7 (5%) were dead, 8 (6%) were loss-follow up Most of 121 children continued to be monitored had clinical and immunological status well changed (p< 0,001) 97,52% (119/121) had WHO clinical stage I after 12 months of ART 92,56% (112/121) had L T CD4 ≥ 15% 87,6% of patients had suppressed HIV RNA at 12 months after ART initation with HIV VL <3log cps/mL Outcomes at 12 months RESULTS

The 6 th National Scientific Conference on HIV/AIDS Number of children with DR mutations Prevalence % Mutation NRTI21,47T215A NNRTI10,74N348I PI42,94 M46L, K20I, T74S Total75,15 HIVDR at ART initiation

The 6 th National Scientific Conference on HIV/AIDS Number of children with DR mutations Prevalence % Mutation NRTI75.15T69N, V75L NNRTI21.47V179D/E Both NRTI & NNRTI 10.74N348I PI53.68L10I/V, L33I Total Mutation associated with resistance

The 6 th National Scientific Conference on HIV/AIDS Of 9 of children with TB and TB treatment in parallel with ART, there were 5 cases (55.56%) had DRMs => 6 times compared with the proportion of non-TB patients B had DRMs (p = 0.01) HIVDR outcomes after 12 months of ART Number of children had DR mutations % NRTIs97,44 Dual resistance to both NRTIs & NNRTIs 64,96 PIs00 RESULTS

The 6 th National Scientific Conference on HIV/AIDS Drug Resistance Mutations 12/15 samples with VL ≥3log cps/mL RESULTS

The 6 th National Scientific Conference on HIV/AIDS DRM Interpretation Resistance to NRTIs At ART initiation: T215A, T69N và V75L. T215A: low-level resistance to D4T & AZT, potential low-level resistance to ABC & DDI (ART naive). T69N: potential low-level resistance to DDI V75L: potential low-level resistance to D4T & DDI. None of TAMs were recorded.

The 6 th National Scientific Conference on HIV/AIDS DRM Interpretation After 12months of ART: D67N, K70R, L74V, V75M, V75T, Y115F, Q151M, M184V, T215F, T215S & T215N. M184V: detected in 6/12 cases (50%), selected by 3TC and reduces susceptibility to this drugs >1000-fold. It is also selected by, and causes low-level resistance to, ABC and ddI V75M: high-level resistance to d4T and medium-level resistance to ddI. Q151M: intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with mutations at the associated positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate-level resistance to TDF, 3TC and FTC. PED1-025 had Q151M, F77L and F116FY. TAMs: D67N, K70R, T215F, K219Q. PED2-003 had 3 TAMs (D67N, K70R and K219Q)

The 6 th National Scientific Conference on HIV/AIDS Resistance to NNRTIs Low genetic barrier, 1 primary mutation  reduced susceptibility to the relevant NNRTIs. At ART initiation: Primary mutation : N348I  low-level resistance to NVP, potential low-level resistance to EFV and AZT, D4T. V179D/E potential low-level resistance to all of 4 NNRTIs After 12months of ART: 5/9 of primary mutation to NNRTIs were detected: K101E, K103N, Y181V, Y188L and G190A => multi DR with all regimens of NNRTIs

The 6 th National Scientific Conference on HIV/AIDS Resistance to PIs At ART initiation: Major mutation: M46L: nonpolymorphic PI-selected mutations that reduce susceptibility to IDV, NFV, FPV, LPV and ATV when present with other mutations. M46L also reduces susceptibility to TPV. Minor mutations: K20I is a PI-selected mutation that appears to reduce NFV susceptibility; T74S is a polymorphic mutation weakly selected by most PIs and associated with low-level resistance to NFV. L10I/V, L33I  not effect on PI susceptibility

The 6 th National Scientific Conference on HIV/AIDS Resistance to PIs After 12 months of ART: Major mutation: not detected. Minor mutation: only L10I/V recorded  not effect on PI susceptibility

The 6 th National Scientific Conference on HIV/AIDS Most of HIV-infected children were detected late with high viral load, compromised immunity, late clinical stage due to accessing testing, care and treatment services late.  Need more interventions to increase accessibility to care - treatment programs for children born to HIV infected mothers. CONCLUSION (1) 5. Conclusions & Recommendations (1)

The 6 th National Scientific Conference on HIV/AIDS Low level of HIVDR were observed among children after 12 months of ART. HIVDR associated mutations related to multi - drug resistance were recorded and dual class resistance, including combined NRTI and NNRTI, was present after only 12 months of ART  Continue to monitor HIVDR in children to provide the information needed to contribute to the HIV treatment guidelines for children in the actual conditions of Vietnam. CONCLUSION (2) 5. Conclusions & Recommendations (2)

The 6 th National Scientific Conference on HIV/AIDS Having TB and TB treatment in parallel with ART seemed to relate to the emergence of HIV drug resistance  Need to be considered in the National ARV treatment guidelines CONCLUSION (3) 5. Conclusions & Recommendations (3)

The 6 th National Scientific Conference on HIV/AIDS THANK YOU